Table 2.
Serum | Liver | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(+/+) | (+/−) | (−/−) | (+/+) | (+/−) | (−/−) | |||||||
(−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | |
d18 : 2 | 7 | 9 | 8 | 7 | 8 | 7 | 12 | 11 | 12 | 13 | 11 | 12 |
d18 : 1 | 34 | 31 | 33 | 36 | 33 | 35 | 29 | 30 | 30 | 28 | 30 | 31 |
d18 : 0 | 11 | 11 | 12 | 10 | 11 | 10 | 11 | 10 | 12 | 11 | 10 | 12 |
t18 : 0 | 7 | 9 | 8 | 7 | 8 | 7 | 6 | 6 | 6 | 5 | 7 | 6 |
d20 : 1 | 8 | 11 | 9 | 8 | 9 | 8 | 12 | 11 | 10 | 12 | 10 | 10 |
d20 : 0 | 5 | 7 | 6 | 6 | 6 | 6 | 10 | 9 | 9 | 10 | 9 | 8 |
t20 : 0 | 28 | 22 | 24 | 26 | 25 | 27 | 20 | 23 | 21 | 21 | 23 | 21 |
(−): mice treated with a control diet; (+): mice treated with fenofibrate; d18 : 2: sphingadienine; d18 : 1: (4E)-sphingenine; d18 : 0: sphinganine; t18 : 0: 4D-hydroxysphinganine; d20 : 1: (4E)-icosasphingenine; d20 : 0: icosasphinganine; t20 : 0: 4D-hydroxyicosasphinganine.
Data are expressed as percentages.